Abivax SA (ABVX)
NASDAQ: ABVX · IEX Real-Time Price · USD
14.00
-0.28 (-1.96%)
At close: May 9, 2024, 3:59 PM
13.98
-0.02 (-0.14%)
After-hours: May 9, 2024, 4:00 PM EDT
Abivax Revenue
In the year 2023, Abivax had annual revenue of $5.13M with 5.31% growth.
Revenue (ttm)
$5.13M
Revenue Growth
+5.31%
P/S Ratio
173.27
Revenue / Employee
$84,171
Employees
61
Market Cap
890.28M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.13M | 258.91K | 5.31% |
Dec 31, 2022 | 4.88M | -8.72M | -64.13% |
Dec 31, 2021 | 13.59M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionABVX News
- 5 weeks ago - Abivax reports 2023 financial results and operational update - GlobeNewsWire
- 3 months ago - Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO) - Accesswire
- 7 months ago - Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire
- 7 months ago - Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market - Accesswire
- 7 months ago - Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris - Accesswire
- 7 months ago - Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market - Accesswire
- 7 months ago - Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris - Accesswire
- 7 months ago - Abivax increases size of Nasdaq uplisting deal - Market Watch